FIGURE 1: METHOD FOR WHOLE-BRAIN PHARMACOMAPS REPRESENTING DRUG-EVOKED BRAIN ACTIVATION IN THE MOUSE.




FIGURE 2: KETAMINE DOSE-CURVE PHARMACOMAPS.




FIGURE 3: GABOXADOL AND KETAMINE SIDE-BY-SIDE PHARMACOMAP COMPARISON




FIGURE 4: SYNERGISTIC EFFECT OF CO-APPLICATION OF GABOXADOL AND KETAMINE AT SUB-THRESHOLD DOSES




FIGURE 5: FORCED SWIM TEST





FIGURE 6:


Mean Plasma Concentrations of Cabozantinib Following Administration of 15-mg Single Oral Doses to Healthy Subjects (n=24)
Mean Cabozantinib Plasma Concentration (ng/mL)
Time (hr)
ODT
Monohydrate Capsule
0
50
100
150
200
250
300
2
4
6
8
10
12
14
16
1000
100
10
1